

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 DECEMBER 2014 ERRATA

(1) This Erratum removes *APO-Osteo Paracetamol 665 mg*, *Blooms the Chemist Osteo Pain Relief Paracetamol 665 mg*, *Chem mart Pharmacy Osteo Relief Paracetamol 665 mg* and *Terry White Chemists Osteo Relief Paracetamol 665 mg* brands from PBS items 8814X, 5343F and 5344G in the 1 December 2014 PBS Schedule. The entries for *paracetamol 665 mg tablet: modified release, 96 tablets* should appear as follows:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
8814X NP	PARACETAMOL Restricted benefit Relief of persistent pain associated with osteoarthritis paracetamol 665 mg tablet: modified release, 96 tablets	2	5	..	*15.34	16.49	^a Osteomol 665 Paracetamol	CR
				^B 1.64	*16.98	16.49	^a Panadol Osteo	GC
5343F NP	PARACETAMOL Authority required (STREAMLINED) 3649 Initial supply, for up to 4 months, for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated paracetamol 665 mg tablet: modified release, 96 tablets	2	3	..	*15.34	16.49	^a Osteomol 665 Paracetamol	CR
				^B 1.64	*16.98	16.49	^a Panadol Osteo	GC
5344G NP	PARACETAMOL Authority required (STREAMLINED) 3650 Continuing supply for a palliative care patient for analgesia or fever where alternative therapy cannot be tolerated Note Written or telephone authority applications for increased repeats may be approved where consultation with a palliative care specialist or service has occurred. paracetamol 665 mg tablet: modified release, 96 tablets	2	*15.34	16.49	^a Osteomol 665 Paracetamol	CR
				^B 1.64	*16.98	16.49	^a Panadol Osteo	GC

(2) This Erratum corrects the entry in the 1 December 2014 Schedule for Pramipexole by removing *Simplral* brand from PBS items 9393J and 9394K. The entry for these items should appear as follows:

PBS Item Code	Name, Restriction, Manner of Administration and Form	Max Qty (Packs)	No. of Rpts	Premium	Dispensed Price for Max Quantity	Maximum Recordable Value for Safety Net	Brand Name	Manufacturer
	<p>PRAMIPEXOLE Restricted benefit Treatment of severe primary Restless Legs Syndrome in a patient who manifests all 4 diagnostic criteria below and whose baseline International Restless Legs Syndrome Rating Scale (IRLSRS) score is greater than or equal to 21 points prior to initiation of pramipexole. The date and IRLSRS score must be documented in the patient's medical records at the time pramipexole treatment is initiated. The diagnostic criteria for Restless Legs Syndrome are:</p> <p>(a) An urge to move the legs usually accompanied or caused by unpleasant sensations in the legs; and (b) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting; and (c) The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues; and (d) The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur during the evening or night. Pramipexole is not PBS-subsidised for Restless Legs Syndrome secondary to other causes</p> <p>Caution Episodes of sudden onset of sleep without warning, during activity, have been reported with this drug.</p> <p>Note Care should be taken when treating patients with advanced age and significant cognitive impairment with dopamine agonists.</p> <p>Note No applications for increased maximum quantities and/or repeats will be authorised.</p> <p>Note Continuing Therapy Only: For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners.</p>							
9393J NP	pramipexole hydrochloride monohydrate 125 microgram tablet, 30	1	2	..	11.23	12.38	Sifrol	BY
9394K NP	pramipexole hydrochloride monohydrate 250 microgram tablet, 100	1	2	..	36.07	36.90	Sifrol	BY

(3) This Erratum corrects the entry in the 1 December 2014 Schedule for Olanzapine.

The following Note should appear in the Schedule entry for all Olanzapine items. The Note was omitted for items 1024X, 1037N, 1041T, 1042W, 3381Y, 3382B, 3384D, and 3385E.

Note
Shared Care Model:
For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalised arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

(4) This Erratum corrects the entry in the 1 December 2014 Schedule for Tocilizumab.

The Notes with the heading “TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE RHEUMATOID ARTHRITIS” and with the subheadings:

- (1) How to prescribe PBS-subsidised bDMARD therapy after 1 August 2010.
- (2) Swapping therapy.
- (3) Baseline measurements to determine response.

are not relevant to the section 100 Highly Specialised Drugs listing of Tocilizumab for systemic juvenile idiopathic arthritis. These Notes do not apply to the PBS availability of items 1423X, 1464C, 1419Q, 1481Y, 1482B and 1476Q.